The table below shows Monte Rosa Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$37.37M
-$45.49M
-$38.16M
-$23.41M
-$27.40M
-$13.81M
Capital expenditure
$1.87M
$1.59M
$1.38M
$9.18M
$1.69M
$2.22M
Investing cash flow
-$261.00M
-$100.23M
$9.85M
$20.33M
-$180.52M
-$2.22M
Dividends paid
$0.00
$0.00
$0.00
GLUE operating cash flow (10-K history)
Monte Rosa Therapeutics, Inc. reported operating cash flow of -$22.80M for fiscal year 2025. That is down 154.3% from $42.00M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow grew from -$23.05M (FY 2020) to -$22.80M. Figures come from the company's audited annual reports as filed with the SEC.
